Dear stakeholders,
As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TS ID 12007 - Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer.
For information, the company have advised that they are no longer seeking to launch this product in the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme.
| Status | Suspended |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Further information | Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TS ID 12007 - Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer. For information, the company have advised that they are no longer seeking to launch this product in the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
| Process | STA Standard |
Project Team
| Project lead | Danielle Lees |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 June 2024 | Suspended. Dear stakeholders, As you will be aware, the Department for Health & Social Care has asked NICE to carry out a Single Technology Appraisal of TS ID 12007 - Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer. For information, the company have advised that they are no longer seeking to launch this product in the UK. Therefore, NICE has decided to suspend this appraisal from its current work programme. |
For further information on how we select topics for development, please see our page about topic selection